Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future
- 1 September 2013
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 35 (9) , 1258-1270
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsLeukemia, 2012
- Signaling by the tumor necrosis factor receptor superfamily in B‐cell biology and diseaseImmunological Reviews, 2011
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaClinical Cancer Research, 2011
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemiaLeukemia, 2009
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemiaBlood, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemiaBlood, 2008
- Signal transduction by lymphocyte antigen receptorsCell, 1994